002432 九安医疗
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入301,483-40.54%1,365,5892,592,1963,231,12526,315,361
减:营业总成本361,007-18.39%1,634,0941,884,2142,186,3117,434,730
    其中:营业成本93,463-37.60%493,971760,1981,176,5725,367,195
               财务费用59,870-293.75%(31,807)(6,631)(199,522)(209,149)
               资产减值损失(199)-62.83%(34,568)(53,479)(309,867)(321,559)
公允价值变动收益300,155435.09%2,113,543739,622309,288(326,401)
投资收益149,075-19.83%718,395712,471560,73893,483
    其中:对联营企业和合营企业的投资收益----(910)(1,990)--(1,266)
营业利润389,80728.41%2,535,3922,109,8021,613,49118,311,869
利润总额385,86127.14%2,527,2592,106,8701,580,34418,257,857
减:所得税费用81,404216.92%257,754306,828231,1121,773,763
净利润304,4579.59%2,269,5041,800,0421,349,23216,484,094
减:非控股权益10,924-5.28%2,756131,31597,624453,925
股东净利润293,53310.23%2,266,7481,668,7271,251,60816,030,169

市场价值指针
每股收益 (元) *0.70116.11%5.2293.8142.81535.138
每股派息 (元) *----1.6500.2000.3002.500
每股净资产 (元) *46.4952.69%46.95742.07939.38140.357
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容